Rea­ta con­tin­ues to hit FDA road­blocks with its Friedre­ich’s atax­ia can­di­date, not­ing reg­u­la­tor 'con­cern­s'

Rea­ta Phar­ma­ceu­ti­cals is fac­ing an FDA wall on its small mol­e­cule can­di­date to treat Friedre­ich’s atax­ia, omavelox­olone. Ac­cord­ing to the com­pa­ny’s Q2 re­port, the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER